Colchicine shows promise as a treatment for at-home COVID-19 patients

Home > Press room > Colchicine shows promise as a treatment for at-home COVID-19 patients

November 28, 2020

Recruitment of participants in the COLCORONA phase 3 study likely to end in 2020

The Montreal Heart Institute today announced that the COLCORONA clinical trial will continue to recruit non-hospitalized adult patients with COVID-19 as recommended by the independent data monitoring committee (DMC), following a second interim analysis.

“With the dramatic rise in COVID-19 cases across the world, it is becoming even more critical that we continue to investigate treatments that can not only help those hospitalized with severe disease, but also those with less severe symptoms who are able to remain at home”, said Dr. Jean-Claude Tardif, Director of the Research Center at MHI, Professor of Medicine at the University of Montreal, and COLCORONA principal investigator. “We aim at completing patient recruitment in this large study within the next month and hope that colchicine will reduce the risk of COVID-19 complications.”

find out more by visiting the Institute’s website

Get all the latest news!

By signing up for our newsletter, you’ll be getting the latest news about the Foundation delivered directly to your inbox.

This field is required
This field is required
This field is requiredAdresse courriel invalide

By submitting your information, you consent to receiving communications from us. You may unsubscribe from our communications at any time.
Please leave this
field empty